The Study Regarding Influence on Safety and Efficacy ofSwitching from Pregabalin to Mirogabalin in Patients withPeripheral Neuropathic Pain

Kimura Yoshiyuki0 个研究点目标入组 152 人开始时间: 2019年10月8日最近更新: 2023年10月17日

适应症

试验速览

Mirogabalin switching from pregabalin is generally well tolerated and effective in pain management for peripheral neuropathic pain.

•1) Patients diagnosed with Peripheral Neuropathic Pain.
•2) Patients who is administrated Pregabalin for more than 28 days at enrollment of the study.
•3) Patients with more than 40mm of VAS at informed consent and enrollment.
•4)Patients with 20 years old or older at enrollment.
•5)Patients who give their voluntary Written consent to participate in the study, also patients who are able to understand the procedure of the clinical study and answer a question appropriately.

•1) Patients who have past history of hypersensitivity to ingredients of Mirogabalin and Pregabalin.
•2) Patients who have difficuly participating in the study due to severe complication of Liver Disease, Kidney Disease and Heart Disease.
•3) Patients with creatinine clearance less than 30mL/min by Cockroft-Gault Equation at enrollment.
•4) Pregnancy patients or patients who have possibility of pregnancy.
•5) Nursing mothers.
•6) Patients who are inappropriate for participation in the study for other reason in the opinion of the investigator or sub-investigator.

发起方

Kimura Yoshiyuki